Century Therapeutics (IPSC) Profit After Tax (2020 - 2026)

Century Therapeutics (IPSC) has reported Profit After Tax for 7 consecutive years, with -$21.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 128.28% year-over-year to -$21.6 million; the TTM figure through Mar 2026 stood at -$108.1 million (down 382.49% YoY), while the FY2025 annual figure was -$9.9 million, up 92.19% from the prior year.
• Profit After Tax declined to -$21.6 million in Q1 2026 per IPSC's latest filing, from -$19.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $76.5 million in Q1 2025 and bottomed at -$38.0 million in Q4 2023.
• Historically, Profit After Tax has averaged -$24.9 million across 5 years, with a median of -$31.2 million in 2024.
• Annual changes were most pronounced in 2025 — Profit After Tax surged 372.76% — and 2026, when it slumped 128.28%.
• Century Therapeutics' Profit After Tax stood at -$30.5 million in 2022, then fell by 24.37% to -$38.0 million in 2023, then grew by 3.89% to -$36.5 million in 2024, then jumped by 46.68% to -$19.5 million in 2025, then dropped by 11.2% to -$21.6 million in 2026.
• Business Quant data shows IPSC's Profit After Tax at -$21.6 million in Q1 2026, -$19.5 million in Q4 2025, and -$34.4 million in Q3 2025.